Statistically significant heterogeneity was observed between trials of the following analyses using the Q statistic: Oct-4 with cancer stage III/IV, positive/high Oct-4 versus negative/low Oct-4 (P = 0.19, I2 = 29%); Oct-4 with primary tumor (T3–4), positive/high Oct-4 versus negative/low Oct-4 (P = 0.01, I2 = 64%); Oct-4 with cancer grade of differentiation, positive/high Oct-4 versus negative/low Oct-4 (P = 0.003, I2 = 69%). The gene discussed is POU5F1; the disease is cancer.